Catalog No.
Product Name
Application
Product Information
Citations
-
ROCK2 Inhibitor
ROCK2-IN-6 hydrochloride is a selective inhibitor of Rho-associated protein kinase 2 (ROCK2). It modulates ROCK2 activity, making it a valuable tool for studying disorders associated with ROCK signaling, including autoimmune diseases and inflammation. This compound is ideal for research aimed at understanding the role of ROCK2 in various biological processes and therapeutic interventions. -
ROCK2 Inhibitor
ROCK2-IN-8 is an orally active inhibitor of Rho-associated protein kinase 2 (ROCK2) with an IC50 of 7.2 nM. This compound is valuable in studies investigating aqueous humor outflow in porcine eyes, as well as the phosphorylation of myosin light chain. Its specificity for ROCK2 makes it a useful tool in exploring the roles of this kinase in various biological processes. -
ROCK1 Inhibitor
GSK-25 is a potent and selective inhibitor of ROCK1, demonstrating an IC50 of 7 nM. This compound exhibits excellent selectivity against a diverse panel of 31 kinases, with over 100-fold selectivity compared to RSK1 (IC50 = 398 nM) and p70S6K (IC50 = 1 µM). GSK-25 is also characterized by its inhibitory effects on specific cytochrome P450 enzymes, with IC50 values of 2.5 µM, 5.2 µM, and 2.5 µM for CYP2C9, CYP2D6, and CYP3A4, respectively. This makes GSK-25 suitable for research applications focused on cell signaling and pharmacological studies involving the ROCK pathway. -
ROCK1 Inhibitor
ROCK1-IN-1 is a selective ROCK1 inhibitor with a Ki value of 540 nM. This compound is utilized in research focused on hypertension, glaucoma, and erectile dysfunction by modulating the Rho-associated protein kinase pathway. Its inhibition of ROCK1 activity provides insight into various physiological processes and potential therapeutic interventions for related disorders. -
ROCK2 Inhibitor
NRL-1049 is a selective inhibitor of ROCK2, demonstrating an IC50 of 0.59 µM for ROCK2 and 26 µM for ROCK1. This compound effectively reduces Lysophosphatidic acid-induced ROCK activation in endothelial cells and has shown potential in animal models by decreasing lesion volume and hemorrhagic transformation associated with cavernous angiomas. Additionally, NRL-1049 preserves the blood-brain barrier, suppresses seizure activity following brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice, making it a valuable tool for research into neurological disorders and vascular pathologies. -
ROCK Inhibitor
ROCK-IN-1 is a highly selective inhibitor of Rho-associated protein kinase (ROCK), demonstrating an IC50 of 1.2 nM specifically for ROCK2. This compound is valuable for studying the role of ROCK in cellular processes such as cytoskeletal dynamics, apoptosis, and smooth muscle contraction. ROCK-IN-1 is particularly useful in investigations related to cardiovascular diseases, cancer research, and neurological disorders. -
ROCK Inhibitor
Rhodblock 6 is a selective Rho kinase (ROCK) inhibitor that targets the phosphorylation of myosin regulatory light chain (MRLC), impacting its localization within cells. By modulating ROCK activity, this compound plays a critical role in the regulation of cytoskeletal dynamics, making it valuable for research applications involving cellular movement, morphology, and signal transduction pathways. Rhodblock 6 is instrumental in studies focused on cancer metastasis, cardiovascular diseases, and neurological disorders. -
RhoA/ROCK Inhibitor
Fasudil hydrochloride semihydrate is a nonspecific inhibitor of RhoA and Rho-associated protein kinase (ROCK), exhibiting a Ki value of 0.33 μM for ROCK1. It shows inhibitory effects on various protein kinases, demonstrating IC50 values of 0.158 μM for ROCK2, and higher values for PKA, PKC, and PKG. Additionally, Fasudil acts as a potent antagonist of calcium channels and displays vasodilatory properties, making it relevant in studies of cardiovascular function and cellular signaling pathways. -
ROCK Inhibitor
Verosudil hydrochloride is a potent ROCK inhibitor, exhibiting strong inhibitory activity against both ROCK1 and ROCK2, with a Ki of 2 nM. It shows lower selectivity for other kinases, including PKA and CAM2A. By increasing trabecular outflow capacity, Verosudil hydrochloride effectively reduces intraocular pressure. This compound is particularly valuable for research focused on glaucoma and ocular hypertension. -
ROCK2 Inhibitor
BIPM is a potent inhibitor of ROCK2, a key regulator of cytoskeletal dynamics. This compound has been shown to significantly influence neurite length, enhance cell migration, and alter the formation of actin stress fibers. BIPM is valuable in research focused on cancer metastasis and is instrumental in elucidating mechanisms of cellular movement and morphology. -
ROCK1/ROCK2 Inhibitor
LASSBio-2382 is a dual inhibitor of ROCK1 and ROCK2, exhibiting IC50 values of 0.005 μM and 0.003 μM, respectively. This compound effectively diminishes the viability and migratory capacity of cancer cells, making it a valuable tool for investigating aggressive cancer types. Its specific application includes research focused on triple-negative breast cancer, facilitating the study of cellular mechanisms and potential therapeutic strategies. -
ROCK2 Inhibitor
ROCK2-IN-6 is a selective inhibitor of the Rho-associated protein kinase 2 (ROCK2), targeting the ROCK signaling pathway. This compound demonstrates potent inhibition of ROCK2 activity, making it valuable for the study of ROCK-mediated diseases, including autoimmune disorders and inflammation. Its application in research provides insights into the molecular mechanisms underlying these conditions, aiding the development of potential therapeutic strategies. -
ROCK Inhibitor
Y-33075 hydrochloride is a selective inhibitor of the Rho-associated protein kinase (ROCK). It exhibits enhanced potency compared to its predecessor, Y-27632, with an IC50 of 3.6 nM. This compound is utilized in research to elucidate the role of ROCK in various biological processes, including cellular motility, proliferation, and apoptosis. Its application spans studies in cancer, cardiovascular diseases, and neurodegenerative disorders. -
ROCK Inhibitor
ROCK-IN-32 is a potent inhibitor of Rho-associated coiled-coil containing protein kinase 2 (ROCK2), exhibiting an IC50 value of 11 nM. This compound is utilized in research focusing on cardiovascular diseases, cancer, and inflammatory processes. ROCK-IN-32 modulates signaling pathways influenced by ROCK2, making it a valuable tool for investigating the physiological and pathological roles of this kinase in various biological contexts. -
ROCK/GRK Inhibitor
GSK317354A is an inhibitor of Rho-associated protein kinase (ROCK) and G protein-coupled receptor kinase (GRK). This compound exhibits potential therapeutic effects in the context of heart failure and Parkinson's disease, facilitating investigations into its role in modulating signaling pathways associated with these conditions. Researchers can utilize GSK317354A to explore its biological activities and implications for treatment strategies. -
ROCK Inhibitor
ROCK-IN-7 is a selective inhibitor of Rho-associated coiled-coil containing protein kinase (ROCK). This compound demonstrates significant inhibitory activity towards ROCK, making it a valuable tool for investigating its role in ocular diseases, including glaucoma and retinal disorders. Researchers can utilize ROCK-IN-7 to explore therapeutic strategies and molecular mechanisms underlying these conditions. -
ROCK Inhibitor
ROCK-IN-8 is a potent Rho-associated protein kinase (ROCK) inhibitor, exhibiting an IC50 value of less than 100 nM. This compound demonstrates significant anti-inflammatory activity, making it suitable for studies related to various inflammatory conditions. ROCK-IN-8 is particularly relevant for research focused on respiratory and gastrointestinal diseases, contributing to the understanding of the underlying mechanisms of these conditions. -
ROCK2 Inhibitor
Desisopropyle-belumosudil is a selective inhibitor of the Rho-associated protein kinase 2 (ROCK2). This compound exhibits significant biological activity in the regulation of glucose metabolism and has demonstrated potential benefits in mitigating obesity and enhancing insulin sensitivity. It is a valuable tool for researchers investigating metabolic disorders, including diabetes and obesity. -
ROCK Inhibitor
ROCK-IN-9 is a selective inhibitor of Rho-associated protein kinase (ROCK). This compound exhibits cytotoxic effects in HepG2 cells with an IC50 value of 40.8 μM. Additionally, ROCK-IN-9 demonstrates favorable pharmacokinetic properties in murine models, indicating significant in vivo exposure and oral bioavailability at lower doses. Its profile makes it a valuable reagent for research focused on cancer biology and signaling pathways associated with ROCK inhibition. -
ROCK Inhibitor
ROCK-IN-10 is a highly selective inhibitor of Rho-associated protein kinases (ROCK1 and ROCK2), exhibiting IC50 values of 6 nM and 4 nM, respectively. This compound demonstrates over 100-fold selectivity for ROCK over other kinases, making it an invaluable tool for research applications related to cellular signaling, cytoskeletal dynamics, and the study of various pathological conditions, including cancer and cardiovascular diseases. Researchers can utilize ROCK-IN-10 to investigate the role of ROCK in cellular processes and to explore potential therapeutic strategies targeting these kinases. -
ROCK Inhibitor
SB772077B is a selective inhibitor of Rho-associated protein kinase (ROCK), primarily targeting the RhoA/ROCK signaling pathway. This compound exhibits anti-inflammatory properties and enhances aqueous outflow facility, making it relevant for research in glaucoma. Additionally, SB772077B reduces mRNA levels of β-catenin and proteins associated with fibrosis, such as vinculin, fibronectin, collagen 1A, and vimentin. Furthermore, it demonstrates vasodilatory effects and lowers both pulmonary and systemic blood pressure, contributing to its utility in studies related to pulmonary hypertensive disorders. -
ROCK Inhibitor
ROCK-IN-D1 is a potent and selective inhibitor of Rho-associated protein kinase (ROCK). It effectively modulates ROCK activity, leading to decreased downstream phosphorylation events. This compound is valuable for research focused on cellular signaling pathways, vascular biology, and potential therapeutic applications in cancer and cardiovascular diseases. Researchers can leverage ROCK-IN-D1 to elucidate the role of ROCK in various physiological and pathological processes. -
ROCK2 Inhibitor
ROCK2-IN-5 is a selective inhibitor of Rho-associated protein kinase 2 (ROCK2), designed to modulate various cellular pathways implicated in neurodegenerative disorders. This compound exhibits a multitarget profile, integrating structural features from the Rho kinase inhibitor fasudil and the NRF2 inducers caffeic and ferulic acids. ROCK2-IN-5 shows promise in the investigation of amyotrophic lateral sclerosis (ALS), particularly concerning SOD1 mutations, by potentially mitigating cellular stress responses and neuroinflammation associated with the disease. -
ROCK Inhibitor
5-Nitro-1H-indazole-3-carbonitrile is a selective Rho kinase (ROCK) inhibitor, exhibiting an IC50 of 6.67 μM for ROCK-I. This compound demonstrates significant capacity to reduce norepinephrine-induced transient contractions and inhibits calcium-induced contractions in endothelial-denuded rat vascular rings. While it possesses vasorelaxant properties, it is important to note its associated toxicity. 5-Nitro-1H-indazole-3-carbonitrile is relevant for research in cardiovascular diseases, particularly in studies of hypertension. -
ROCK2 Inhibitor
LASSBio-2389 is a selective inhibitor of Rho-associated protein kinase 2 (ROCK2) with an IC50 of 0.051 μM and demonstrates lower potency against ROCK1 with an IC50 of 1.143 μM. This compound effectively reduces the viability of MDA-MB-231 cells and inhibits cell migration, making it a valuable tool for investigating the pathophysiology of triple-negative breast cancer. Its targeted action on ROCK2 positions LASSBio-2389 as a significant reagent in cancer research applications focused on aggressive tumor behaviors. -
ROCK Inhibitor
WF-536 is an orally active inhibitor of Rho-associated coiled-coil-containing protein kinase (ROCK), a key regulator of various cellular functions. This compound exhibits tumor anti-metastatic activity, making it a valuable tool in cancer research. WF-536 is suitable for studies exploring the mechanisms of metastasis and the development of targeted cancer therapies. -
ROCK2 Inhibitor
ROCK2-IN-14 is a selective inhibitor of ROCK2, exhibiting an IC50 of 4.8 nM and 212-fold selectivity over ROCK1. This compound inhibits the ROCK2/S100A9 signaling pathway, leading to downregulation of S100A9 expression, inhibition of NM2 phosphorylation, and restoration of cytoskeletal abnormalities. It demonstrates significant anti-inflammatory effects, including the reduction of cytokines such as IgE, TNF-α, IL-6, and TSLP, and is effective in mitigating ear thickening in mouse models of atopic dermatitis. ROCK2-IN-14 is suitable for studies focused on inflammation and skin disorders. -
ROCK Inhibitor
ROCK-IN-11 is a potent inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, exhibiting an IC50 of ≤ 5 μM. This compound effectively modulates cellular signaling pathways involved in various biological processes, making it a valuable tool in cancer research. Additionally, ROCK-IN-11 can be used to explore therapeutic strategies targeting cell migration, proliferation, and apoptosis. -
ROCK2 Inhibitor
ROCK-IN-6 is a potent and selective inhibitor of ROCK2, exhibiting an IC50 of 2.19 nM. This compound serves as a valuable tool for investigating the role of ROCK2 in various biological processes, particularly in the context of glaucoma and retinal diseases. ROCK-IN-6 is ideal for studies exploring cellular signaling pathways and therapeutic interventions in ocular health. -
ROCK Inhibitor
3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine is a selective inhibitor of Rho-associated protein kinase (ROCK), exhibiting IC50 values of 0.092 μM for PKC-α, 0.26 μM for ROCK, and 0.77 μM for ASK1. This compound demonstrates significant cytotoxic activity against human prostate cancer PC-3 cells, with an IC50 value of 0.16 μM. Its efficacy in inhibiting kinase activity makes it a valuable tool for research in cancer therapeutics and related signaling pathways. -
ROCK Inhibitor
ROCK-IN-D2 is a potent and selective inhibitor of Rho-associated protein kinase (ROCK). This compound exhibits significant biological activity by blocking ROCK-mediated signaling pathways, which are implicated in various cellular processes, including cytoskeletal rearrangement and cell migration. ROCK-IN-D2 is primarily utilized in research applications related to cancer biology, cardiovascular diseases, and neurodegenerative disorders, facilitating the study of ROCK's role in these pathologies. -
ROCK Inhibitor
ROCK-IN-4 is a selective inhibitor of Rho-associated protein kinase (ROCK), exhibiting the capacity to maintain nitric oxide releasing ability. This compound effectively reversibly depolymerizes F-actin and inhibits mitochondrial respiration in human trabecular meshwork (HTM) cells. ROCK-IN-4 is valuable for research related to glaucoma and ocular hypertension, making it a critical tool for investigating cellular mechanisms involved in these conditions. -
ROCK Inhibitor
OXA-06 is a potent ROCK (Rho-associated protein kinase) inhibitor that demonstrates significant antitumor activity. It disrupts cell migration and inhibits MYPT1 phosphorylation in PANC-1 cells, making it a valuable tool for cancer research. This compound can be utilized in studies focusing on the modulation of cellular dynamics and therapeutic strategies for pancreatic cancer. -
ROCK Inhibitor
Ripasudil free base is a selective inhibitor of Rho-associated protein kinase (ROCK), demonstrating IC50 values of 19 nM for ROCK2 and 51 nM for ROCK1. This compound exhibits significant biological activity in modulating cellular processes such as migration and proliferation, making it valuable in research focused on fibrosis, cancer, and cardiovascular diseases. Ripasudil free base is an important tool for studies investigating the role of ROCK signaling in various physiological and pathological contexts. -
ROCK Inhibitor
CMPD101 hydrochloride is a membrane-permeable inhibitor targeting Rho-associated kinase 2 (ROCK-2), G protein-coupled receptor kinase 2 (GRK2), and GRK3, with IC50 values of 1.4 μM, 18 nM, and 5.4 nM, respectively. This small-molecule compound also inhibits protein kinase C alpha (PKCα) at an IC50 of 8.1 μM. CMPD101 hydrochloride is useful in research focused on cell signaling, smooth muscle contraction, and potential therapeutic applications in cardiovascular and neurological disorders. -
RhoA/ROCK Inhibitor
Fasudil mesylate is a potent RhoA/ROCK inhibitor with a Ki value of 0.33 μM for ROCK1 and IC50 values of 0.158 μM for ROCK2, along with notable inhibition of PKA, PKC, and PKG. This orally active compound also acts as a calcium channel antagonist and vasodilator, demonstrating significant potential in cardiovascular research and the study of cellular signaling pathways. Its diverse inhibitory effects make Fasudil mesylate a valuable tool for investigating RhoA/ROCK-related biological processes. -
LIM/ROCK/PKA Inhibitor
LX7101 monohydrochloride is a potent inhibitor of LIM-kinase, ROCK, and PKA, exhibiting IC50 values of 24 nM, 1.6 nM, 10 nM, and <1 nM for LIMK1, LIMK2, ROCK2, and PKA, respectively. This compound demonstrates significant selectivity for LIMK2 with an IC50 of 4.3 nM in contrast to 32 nM for LIMK1 at 2 μM ATP. LX7101 monohydrochloride is valuable for research into ocular hypertension and associated glaucoma, providing insights into potential therapeutic strategies targeting these pathways. -
TGF-β/Smad Agonist
SRI-011381 is an orally active agonist of the TGF-β/Smad signaling pathway. It has been shown to exhibit neuroprotective effects, making it a valuable tool for research in neurobiology and regenerative medicine. This compound can be utilized to investigate the role of TGF-β in various cellular processes and potential therapeutic applications in neurodegenerative diseases. -
Smad2/3 Inhibitor
Luspatercept is a recombinant modified ActRIIB fusion protein that functions as a Smad2/3 inhibitor. It selectively binds to transforming growth factor β (TGF-β) superfamily ligands, including GDF11, thereby inhibiting Smad2/3 signaling. This compound promotes the maturation of erythroid precursors and increases erythrocyte numbers, making it a valuable tool for research into anemia and related erythropoietic disorders. -
SMAD7 Antisense Oligonucleotide
Mongersen sodium is a targeted SMAD7 antisense oligonucleotide that functions to restore TGF-β1 activity, resulting in the inhibition of inflammatory signaling pathways. This compound has demonstrated efficacy in attenuating experimental colitis resembling Crohn's disease in mouse models. It is a valuable tool for studying inflammatory bowel disease mechanisms and the modulation of TGF-β signaling in various research applications. -
Smad3 Inhibitor
SIS3 free base is a potent and selective inhibitor of Smad3 phosphorylation. It significantly inhibits the myofibroblast differentiation of fibroblasts induced by TGF-β1 while leaving the phosphorylation of Smad2 unaffected. This specificity makes SIS3 free base a valuable tool for studying the role of Smad3 in cellular processes associated with fibrosis and other TGF-β1 mediated pathways. -
Syk Inhibitor, NF-κB p65 Inhibitor, TGF-β1/Smad Signaling Inhibitor
Flavanomarein is a potent inhibitor of Syk and NF-κB p65, as well as a modulator of TGF-β1/Smad signaling pathways. This compound exhibits cytoprotective, anti-inflammatory, and antioxidant activities, enhancing AKT phosphorylation while regulating key proteins such as PKC-δ, P85α, PKC-β1, Sirt1, Bcl-2, and ICAD. Flavanomarein also inhibits the nuclear translocation of NF-κB p65 and modulates epithelial-mesenchymal transition (EMT) markers, promoting proliferation in HK-2 cells and protecting neuronal cells from 6-OHDA-induced neurotoxicity. This compound is valuable for research on Parkinson's disease and diabetic nephropathy. -
TGF-β2 Antisense Aligonucleotide
Trabedersen is an antisense oligodeoxynucleotide that specifically targets and inhibits TGF-β2, a key regulator in the TGF-beta/Smad signaling pathway. This reagent is critical for research in malignant brain tumors and various solid tumors, including those affecting the skin, pancreas, and colon, which exhibit overexpression of TGF-β2. By modulating this pathway, Trabedersen offers insights into tumor biology and potential therapeutic strategies. -
TGF-β Inhibitor
TGFβ-IN-2 is an orally active inhibitor of TGF-β, targeting its signaling pathways. This compound effectively suppresses TGF-β-induced expression of key proteins such as COL1A1, α-SMA, and p-Smad3 in vitro. TGFβ-IN-2 exhibits significant anti-fibrotic effects in a Bleomycin-induced pulmonary fibrosis model, making it a valuable tool for investigating the mechanisms and potential treatments of pulmonary fibrosis. -
SMAD7 Antisense Oligonucleotide
Mongersen is a targeted SMAD7 antisense oligonucleotide that restores TGF-β1 activity, thereby inhibiting inflammatory pathways. This compound has demonstrated the ability to attenuate experimental colitis resembling Crohn's disease in murine models. Its application is particularly relevant in studying inflammation and fibrosis related to gastrointestinal disorders. -
TGF-β1/Smad Signaling Pathway Inhibitor
DGM is a specific inhibitor of the TGF-β1/Smad signaling pathway, exhibiting notable antifibrotic properties. It effectively inhibits the epithelial-mesenchymal transition (EMT) in alveolar epithelial cells, thereby slowing the progression of pulmonary fibrosis in vivo. DGM reduces lung inflammation, enhances lung function, and minimizes extracellular matrix remodeling, making it a valuable tool for research on idiopathic pulmonary fibrosis (IPF) and other EMT-related diseases. -
TGF-β1 Inhibitory Peptide
P17 Peptide is a selective inhibitor of human TGF-β1, functioning by blocking its activity. This peptide is valuable for studying the role of TGF-β1 in various biological processes and disease states, including fibrosis and cancer. Its inhibitory effects facilitate research into therapeutic strategies targeting TGF-β signaling pathways. -
TGF-β1 Inhibitor
DT-6 is a selective inhibitor of TGF-β1, a key regulator of cellular processes related to fibrosis and cancer progression. By inhibiting TGF-β1, DT-6 effectively disrupts M2 macrophage-induced epithelial to mesenchymal transition (EMT) and inhibits the invasive migration of cancer cells. This compound is valuable for research applications focused on cancer biology and related therapeutic interventions. -
TGF-β2 siRNA
ISTH0036 is a selective antisense oligonucleotide targeting transforming growth factor beta 2 (TGF-β2). It exhibits inhibitory activity against TGF-β2 expression, making it a valuable tool for investigating the pathophysiological mechanisms of primary open-angle glaucoma (POAG) and wet age-related macular degeneration. This reagent is suitable for both in vitro and in vivo studies aimed at understanding the role of TGF-β2 in these ocular conditions. -
SMAD2 activator
Myristoyl tetrapeptide-12 is a specific activator of SMAD2, promoting the recruitment of SMAD3 to DNA. This peptide exhibits significant biological activity in stimulating hair growth, with notable effects on eyelash enhancement. Its applications are particularly relevant in research focusing on hair follicle biology and regenerative medicine.
